Search results
Results from the WOW.Com Content Network
The main efficacy measurement was the time to death from cardiovascular causes or need to be hospitalized for heart failure. [33] Of the individuals who received empagliflozin for an average of about two years, 14% died from cardiovascular causes or were hospitalized for heart failure, compared to 17% of the participants who received the ...
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. . Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to the existing treatment
In a statement on Friday, the two partners said Jardiance cut the risk of kidney disease progression and cardiovascular death by 28%, citing results from a late-stage trial which included people ...
In the trial, Jardiance cut the combined risk of cardiovascular death or hospitalization from heart failure in HFpEF patients with or without diabetes. At the 26-month mark, 13.8% of Jardiance ...
GLP-1 users have also reported a decreased libido, irritability, and being quieter or more monotone, according to experiences shared on a Reddit post. “I feel more subdued and almost like I lost ...
Irritability. People with low moods can be quicker to anger, even over something that might seem trivial. Engaging in reckless behavior. Overuse of alcohol, drugs, or other self-harming behavior ...
Postnatal adaptation syndrome (PNAS) (originally called "neonatal behavioral syndrome", "poor neonatal adaptation syndrome", or "neonatal withdrawal syndrome") was first noticed in 1973 in newborns of mothers taking antidepressants; symptoms in the infant include irritability, rapid breathing, hypothermia, and blood sugar problems. The symptoms ...